Inetetamab in combination with rapamycin and chemotherapy for trastuzumab‐treated metastatic <scp>human epidermal growth factor receptor 2</scp>‐positive breast cancer with abnormal activation of <scp>PI3K/Akt/mTOR</scp> pathway
Cancer reports